Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Patients with moderate hepatic impairment showed mildly increased AUC_0-inf for rucaparib compared to patients with normal hepatic function. Although more patients with moderate hepatic impairment experienced TEAEs, only 2 TEAEs were considered treatment related. These results suggest no starting dose adjustment is necessary for patients with moderate hepatic impairment; however, close safety monitoring is warranted.